|
|
||||||||||
|
J Am Coll Cardiol, 2004; 43:2253-2259, doi:10.1016/j.jacc.2004.02.046 © 2004 by the American College of Cardiology Foundation |



,*
* National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
Suburban Hospital, Bethesda, Maryland, USA
Manuscript received April 4, 2003; revised manuscript received December 24, 2003, accepted February 3, 2004.
* Reprint requests and correspondence: Dr. Andrew E. Arai, Laboratory of Cardiac Energetics, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, MSC 1061, Building 10, Room B1D-416, Bethesda, Maryland 20892-1061, USA.
araia{at}nih.gov
| Abstract |
|---|
|
|
|---|
BACKGROUND: Cardiac magnetic resonance accurately determines myocardial viability in patients with chronic ischemic heart disease but is not well validated for recent MI.
METHODS: Patients with first acute MI (n = 33) or chronic MI (n = 10) underwent cine CMR followed by gadolinium delayed enhancement imaging. A follow-up CMR scan was performed on 20 of the 33 acute MI patients and all of the chronic MI patients.
RESULTS: In patients with acute percutaneous coronary intervention, acute MI mass correlated with peak troponin I (r = 0.83, p < 0.001, n = 23). In the 20 acute infarct patients with follow-up CMR scans, the acute infarct size correlated well with the follow-up LV ejection fraction (r = 0.86, p < 0.001). The transmural extent of delayed enhancement imaged acutely correlated inversely with wall thickening measured acutely (p < 0.001) and at follow-up (p < 0.001). Although chronic infarct size was reproducible (11 ± 4% vs. 12 ± 7%, p = NS), acute infarct size decreased from 16 ± 12% to 11 ± 9% (p < 0.003).
CONCLUSION: In humans imaged shortly after acute MI, gadolinium delayed enhancement acute CMR infarct size correlates with acute and chronic indices of infarct size but will appear to diminish in size on follow-up.
| ||||||||||
| Methods |
|---|
|
|
|---|
The 33 subjects were selected to analyze correlations with peak troponin I and further subdivided based on whether they received acute revascularization (n = 23), because it was postulated that reperfusion status might influence the dynamics of serum troponin I levels.
Temporal changes in MI mass and the relationship to acute and regional left ventricular (LV) function were studied in the subgroup of 20 patients that returned for a CMR scan more than two months after the acute study. The time span of two months was chosen to allow for recovery of function in stunned myocardium. To be eligible for follow-up, the patients could have no clinically recognized ischemic events in the interval time period.
To determine the reproducibility of the CMR analysis, a separate control group of 10 patients with known chronic MIs were imaged on two CMR scans more than two months apart. Only those patients with no documented interval MI were eligible for follow-up imaging.
Myocardial infarction was diagnosed by history, electrocardiographic changes, and cardiac enzyme abnormalities in accordance with the consensus of the American College of Cardiology and the European Society of Cardiology (1). Troponin I was measured, by emergency department protocol, every 4 h and continued for 8 h after acute interventions.
Acute percutaneous coronary interventions and subsequent revascularization procedures were based upon standard clinical indications as determined by the attending cardiologist. Acute percutaneous reperfusion was defined by coronary angioplasty or stenting within 6 h of presentation. Subacute revascularization was defined as occurring 6 h to one month after the initial event.
Functional CMR. The CMR was performed using a GE (General Electric Medical Systems, Waukesha, Wisconsin) CV/i 1.5-T scanner and a four-element cardiac phased array coil. Functional assessment of the LV was performed pre-contrast using cine CMR with either fast gradient echo (n = 6) or steady-state free precession imaging (n = 27). Imaging was performed in multiple short breath-holds. The in-plane resolution was approximately 2 mm (26 µl/voxel), and the temporal resolution was 40 to 50 ms within the cardiac cycle. The heart was imaged in multiple parallel short-axis planes 8-mm thick separated by 3-mm gaps, as well as in the two-chamber, three-chamber, and four-chamber long-axis views.
Gadolinium delayed enhancement CMR. Myocardial infarction was imaged using an inversion recovery fast gradient echo sequence triggered every other heartbeat. Images were obtained approximately 20 min after intravenous injection of 0.2 mmol/kg gadolinium diethyltriaminepentaacetic acid (Gd-DTPA). Imaging was performed at end-expiration and lasted about 12 heartbeats. The in-plane image resolution was typically 2.5 mm, and each imaging voxel represented approximately 42 µl of tissue. Volumetric coverage of the entire LV was obtained using a slice thickness of 8 mm and a slice separation of 3 mm. The same slices were acquired for both functional imaging and delayed enhancement to ensure registration between cine CMR and infarct measurements.
Analysis and statistics. Ejection fractions were calculated on the basis of end-diastolic and end-systolic endocardial tracings manually drawn by a cardiologist using computer-assisted planimetry. Wall thickening was quantified from endocardial and epicardial tracings using a centerline analysis (2). The LV wall thickening was summarized using the 16-segment model of the American Society of Echocardiography (3). The change in wall thickening between the two CMR scans was analyzed on segments with <1 mm of wall thickening on the acute study. To minimize the influence of heterogeneous tissue within the relatively large segments of the 16-segment model, focal one-dimensional measurements of wall thickening were also made at the core of the MI. The core of the MI was defined as the location in which there was maximal transmural extent of delayed enhancement.
Delayed enhancement images were displayed with a gray scale to optimally show normal myocardium (dark) and the region of delayed enhancement myocardium (bright). Infarct size was quantified using computer-assisted planimetry and reported in units of grams of infarcted myocardium. Infarct size was also summarized as percent of LV mass that appeared infarcted. Qualitatively, the segments were categorized according to the transmural extent of delayed enhancement: 0%, 1% to 25%, 26% to 50%, 51% to 75%, and 76% to 100%.
Summary statistical indices were calculated using a paired t test and linear regression in SigmaStat for Windows v2.03 (SPSS Inc., Chicago, Illinois). Values of p > 0.05 were considered not significant.
| Results |
|---|
|
|
|---|
|
Correlation between infarct size and troponin I. Correlations between peak troponin I and CMR infarct size were studied in the 33 patients with first MI. Twenty-three of these patients had acute percutaneous interventions and 10 did not. Median troponin I was 42 (range 2.0 to 745 ng/ml; where normal is 0.00 to 0.40 ng/ml). For reperfused infarcts (Fig. 1a), the correlation between troponin I and infarct size was r = 0.83 and p < 0.001 (excluding the 745 ng/ml point which was deemed an outlier that increased the correlation disproportionately). The linear correlation between troponin I and infarct size was not statistically significant for non-reperfused infarcts (p = 0.28).
|
|
Figure 3 shows two time points in the recovery of wall thickening after acute MI. In the acute infarct group, there was an inverse relationship between the transmural extent of delayed enhancement and the measured wall thickening. From segments with no delayed enhancement to segments with progressively greater CMR evidence of infarction, there was a stepwise worsening in regional wall thickening on the acute CMR scan (Fig. 3a) (p < 0.001 for trend). There was also an inverse relationship between the transmural extent of delayed enhancement on the acute CMR study and the regional wall thickening on the follow-up study (Fig. 3b) (p < 0.001 for trend).
|
Because the circumferential extent of segments can be large relative to the extent of infarction and infarcts may straddle segment borders, we also made one-dimensional measurements of wall thickening within the core of the MI. Wall thickening in the core of the infarct changed by 1 mm between the acute infarct study and the follow-up study (2.2 ± 2.3 mm vs. 3.2 ± 2.2 mm, p = 0.05). The transmural extent of delayed enhancement at the core of the infarct was >75% in 14 of the 20 acute infarctions. Similar measurements in the chronic infarct group did not change significantly (1.8 ± 4.4 mm vs. 2.0 ± 4.5 mm, p = 0.29).
CMR infarct size. The 20 acute infarct patients underwent CMR on average 1.7 ± 0.8 days post-MI for the acute study. They were imaged 22 ± 5 min post-contrast after the acute MI and 24 ± 5 min on the follow-up study (p = NS). Eighteen of 20 patients demonstrated a decrease in the CMR infarct size (example shown in Fig. 4).
|
|
| Discussion |
|---|
|
|
|---|
Numerous studies in the literature have shown a correlation between troponin and histopathologic infarct size in canine (4,5) and murine (6) models. In patients, troponin has been correlated against ventriculography (7), thallium (8,9), and sestamibi (10).
This is the first study delineating the relationship between CMR infarct size and serum peak troponin I rather than the MB fraction of creatine kinase (11,12). Fifteen percent of our patients had troponin I levels of
9 ng/ml, which are small infarctions but of significant adverse prognostic value (13). The infarct was visualized on both CMR scans in all patients despite the fact that many had less than 1 g of infarcted myocardium per image. Thus, delayed enhancement can detect many of the smallest acute MIs recognized in humans (14).
Figure 5 raises important questions about the absolute accuracy of gadolinium delayed enhancement determined infarct size in humans. Whereas some studies show close agreement between CMR infarct size and standard measurements (11,12), others have suggested that gadolinium overestimates infarct size in rats (15) and humans (16). Six mechanisms should be considered: 1) involution of the scar tissue into a smaller volume than the original amount of myocardium (17); 2) partial volume effects; 3) through-plane motion errors in assessing wall thickening; 4) mismatch between segment size and infarct size; 5) possible regeneration of cardiomyocytes from primitive progenitor cells (18); and 6) overestimation of infarct size, perhaps as a result of peri-infarct edema (15). High-resolution x-ray spectroscopic analysis indicates that gadolinium closely correlates with sodium and potassium concentrations in the myocardium and suggests peri-infarct edema should not cause overestimation of infarct size by gadolinium-based contrast agents (19).
We believe a combination of involution of infarcted myocardium and partial volume effects can explain the apparent decrease in infarct size and even conversion from apparently transmural infarction to subendocardial infarction (Fig. 6). In our experiments, each imaging voxel represents an average of about 42 µl of tissue. Consider a voxel that contains half normal and half infarcted cardiomyocytes. If the fibrous scar tissue that replaces the infarcted cardiomyocytes has 50% the volume of those cells and the normal cardiomyocytes undergo compensatory hypertrophy that increases their volume by 50%, the infarct could appear to decrease from 50% of the voxel to 25% by the follow-up scan. Because almost all of our patients were reperfused therapeutically or spontaneously, the possibility of mixed viable and nonviable myocytes needs to be considered. These effects will be most prominent in the borders of infarcts, particularly in the transmural direction across the LV wall. Hypertrophy of the viable cells in conjunction with involution of the infarcted cells would account for the relative stability of LV mass over time. Through-plane motion issues could further complicate wall thickening measures.
|
We used regional wall thickening as the primary indicator of viability rather than a change in function because regional wall motion could not be evaluated before acute reperfusion therapy. In normal hearts wall thickening is relatively uniform. Myocardial infarction is the primary cause of regional wall thickening abnormalities, particularly in patients with first MI and full revascularization as in our population. Because there is a graded transmural extent of infarction, it is not unreasonable to expect a graded response in wall thickening for more severe infarctions. This is the basis of the data presented in Figures 3a and 3b. We found an inverse correlation between the transmural extent of delayed enhancement seen on the acute study and regional wall thickening on either scan.
The presence or absence of abnormal delayed enhancement stratified the likelihood and extent of recovery of dysfunctional myocardium (Fig. 3c). Unlike viability studies where regional function can be measured before and after an intervention, differential measurements of wall thickening between the two CMR scans are not appropriate for evaluating viability because the first scan can be predicted to miss early recovery of function associated with mild stunning (23). Note that 44 of 49 segments with <50% delayed enhancement had mild enough wall motion abnormalities to preclude assessment of serial changes. The severity and duration of myocardial stunning generally increases with the severity of the ischemic episode (2427). This can lead to the paradoxical observation that there is more improvement in myocardium that demonstrates the most delayed enhancement (Fig. 3). Regional contractile function improvement in regions with extensive delayed enhancement (Fig. 3) was also observed by Rogers et al. (22) and Choi et al. (11). To keep things in clinical perspective, regions with the most delayed enhancement remained the most dysfunctional segments and had 50% less wall thickening compared with "normal" segments. The amount of improvement in regional wall thickening was small and averaged about 1 mm on each of our quantitative analyses.
| Conclusions |
|---|
|
|
|---|
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. S. Jaffe Key Issues in the Developing Synergism between Cardiovascular Imaging and Biomarkers Clin. Chem., September 1, 2008; 54(9): 1432 - 1442. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H.M. Jansen, F. Bracke, J. m. van Dantzig, K. H. Peels, J. C. Post, H. C.M. van den Bosch, B. van Gelder, A. Meijer, H. H.M. Korsten, J. de Vries, et al. The influence of myocardial scar and dyssynchrony on reverse remodeling in cardiac resynchronization therapy Eur J Echocardiogr, July 1, 2008; 9(4): 483 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Kim, T. S.E. Albert, J. H. Wible, M. D. Elliott, J. C. Allen, J. C. Lee, M. Parker, A. Napoli, R. M. Judd, and for the Gadoversetamide Myocardial Infarction Imag Performance of Delayed-Enhancement Magnetic Resonance Imaging With Gadoversetamide Contrast for the Detection and Assessment of Myocardial Infarction: An International, Multicenter, Double-Blinded, Randomized Trial Circulation, February 5, 2008; 117(5): 629 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Giannitsis, H. Steen, K. Kurz, B. Ivandic, A. C. Simon, S. Futterer, C. Schild, P. Isfort, A. S. Jaffe, and H. A. Katus Cardiac Magnetic Resonance Imaging Study for Quantification of Infarct Size Comparing Directly Serial Versus Single Time-Point Measurements of Cardiac Troponin T J. Am. Coll. Cardiol., January 22, 2008; 51(3): 307 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. George and M. C. Oz Myocardial Revascularization after Acute Myocardial Infarction Card. Surg. Adult, January 1, 2008; 3(2008): 669 - 696. [Full Text] |
||||
![]() |
J. F Younger, S. Plein, J. Barth, J. P Ridgway, S. G Ball, and J. P Greenwood Troponin-I concentration 72 h after myocardial infarction correlates with infarct size and presence of microvascular obstruction Heart, December 1, 2007; 93(12): 1547 - 1551. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Lund, A. Stork, K. Muellerleile, A. A. Barmeyer, M. P. Bansmann, M. Knefel, U. Schlichting, M. Muller, P. E. Verde, G. Adam, et al. Prediction of Left Ventricular Remodeling and Analysis of Infarct Resorption in Patients with Reperfused Myocardial Infarcts by Using Contrast-enhanced MR Imaging Radiology, October 1, 2007; 245(1): 95 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Thiele, M. J. Kappl, A. Linke, S. Erbs, E. Boudriot, A. Lembcke, D. Kivelitz, and G. Schuler Influence of time-to-treatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging Eur. Heart J., June 6, 2007; (2007) ehm173v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Lim, M. B. Srichai, and V. S. Lee Non-Ischemic Causes of Delayed Myocardial Hyperenhancement on MRI Am. J. Roentgenol., June 1, 2007; 188(6): 1675 - 1681. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Assomull, J. C. Lyne, N. Keenan, A. Gulati, N. H. Bunce, S. W. Davies, D. J. Pennell, and S. K. Prasad The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries Eur. Heart J., May 3, 2007; (2007) ehm113v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saeed, D. Saloner, A. Martin, L. Do, O. Weber, P. C. Ursell, A. Jacquier, R. Lee, and C. B. Higgins Adeno-associated Viral Vector-Encoding Vascular Endothelial Growth Factor Gene: Effect on Cardiovascular MR Perfusion and Infarct Resorption Measurements in Swine Radiology, May 1, 2007; 243(2): 451 - 460. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Vartdal, H. Brunvand, E. Pettersen, H.-J. Smith, E. Lyseggen, T. Helle-Valle, H. Skulstad, H. Ihlen, and T. Edvardsen Early Prediction of Infarct Size by Strain Doppler Echocardiography After Coronary Reperfusion J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1715 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Circulation, April 3, 2007; 115(13): e356 - e375. [Full Text] [PDF] |
||||
![]() |
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes Clin. Chem., April 1, 2007; 53(4): 552 - 574. [Full Text] [PDF] |
||||
![]() |
M. Habis, A. Capderou, S. Ghostine, B. Daoud, C. Caussin, J.-Y. Riou, P. Brenot, C. Y. Angel, B. Lancelin, and J.-F. Paul Acute Myocardial Infarction Early Viability Assessment by 64-Slice Computed Tomography Immediately After Coronary Angiography: Comparison With Low-Dose Dobutamine Echocardiography J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1178 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L.M.A. Beeres, F. M. Bengel, J. Bartunek, D. E. Atsma, J. M. Hill, M. Vanderheyden, M. Penicka, M. J. Schalij, W. Wijns, and J. J. Bax Role of Imaging in Cardiac Stem Cell Therapy J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1137 - 1148. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Saha, R Zbinden, S R Redwood, and M S Marber Stem cells to repair the broken heart: much ado about nothing? Heart, December 1, 2006; 92(12): 1717 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saeed, O. Weber, R. Lee, L. Do, A. Martin, D. Saloner, P. Ursell, P. Robert, C. Corot, and C. B. Higgins Discrimination of Myocardial Acute and Chronic (Scar) Infarctions on Delayed Contrast Enhanced Magnetic Resonance Imaging With Intravascular Magnetic Resonance Contrast Media J. Am. Coll. Cardiol., November 21, 2006; 48(10): 1961 - 1968. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ebeling Barbier, T. Bjerner, L. Johansson, L. Lind, and H. Ahlstrom Myocardial Scars More Frequent Than Expected: Magnetic Resonance Imaging Detects Potential Risk Group J. Am. Coll. Cardiol., August 15, 2006; 48(4): 765 - 771. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Jaffe, L. Babuin, and F. S. Apple Biomarkers in Acute Cardiac Disease: The Present and the Future J. Am. Coll. Cardiol., July 4, 2006; 48(1): 1 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Y. Kwong, A. K. Chan, K. A. Brown, C. W. Chan, H. G. Reynolds, S. Tsang, and R. B. Davis Impact of Unrecognized Myocardial Scar Detected by Cardiac Magnetic Resonance Imaging on Event-Free Survival in Patients Presenting With Signs or Symptoms of Coronary Artery Disease Circulation, June 13, 2006; 113(23): 2733 - 2743. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Christian Positively Magnetic North J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1646 - 1648. [Full Text] [PDF] |
||||
![]() |
H. Thiele, M. J.E. Kappl, S. Conradi, J. Niebauer, R. Hambrecht, and G. Schuler Reproducibility of Chronic and Acute Infarct Size Measurement by Delayed Enhancement-Magnetic Resonance Imaging J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1641 - 1645. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Baks, R.-J. van Geuns, E. Biagini, P. Wielopolski, N. R. Mollet, F. Cademartiri, W. J. van der Giessen, G. P. Krestin, P. W. Serruys, D. J. Duncker, et al. Effects of Primary Angioplasty for Acute Myocardial Infarction on Early and Late Infarct Size and Left Ventricular Wall Characteristics J. Am. Coll. Cardiol., January 3, 2006; 47(1): 40 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Baks, R.-J. van Geuns, E. Biagini, P. Wielopolski, N. R. Mollet, F. Cademartiri, W. J. van der Giessen, G. P. Krestin, P. W. Serruys, D. J. Duncker, et al. Effects of Primary Angioplasty for Acute Myocardial Infarction on Early and Late Infarct Size and Left Ventricular Wall Characteristics J. Am. Coll. Cardiol., December 13, 2005; (2005) j.jacc.2005.09.008v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Babuin and A. S. Jaffe Troponin: the biomarker of choice for the detection of cardiac injury Can. Med. Assoc. J., November 8, 2005; 173(10): 1191 - 1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Gibbons and P. A. Araoz The Year in Cardiac Imaging J. Am. Coll. Cardiol., August 2, 2005; 46(3): 542 - 551. [Full Text] [PDF] |
||||
![]() |
A. H. Mahnken, R. Koos, M. Katoh, J. E. Wildberger, E. Spuentrup, A. Buecker, R. W. Gunther, and H. P. Kuhl Assessment of Myocardial Viability |